Dr. Subhakar Mutyala, MD

Dr. Mutyala practices at Medical Oncology / Hematology - Shea in Scottsdale, Arizona.

Dr. Mutyala's NPI, 1851472286, was assigned on October 19, 2006. Dr. Mutyala graduated from Texas A&M College of Medicine - Bryan in 1999. Dr. Mutyala holds Arizona license 50442.

Dr. Mutyala's primary practice is Medical Oncology / Hematology - Shea, at 7337 E 2nd St, Scottsdale, AZ 85251 in Maricopa County. The practice phone is (623) 266-2416.

Dr. Mutyala's primary practice is Medical Oncology / Hematology - Shea in Scottsdale, Arizona. The medical group on file is District Medical Group. Dmand AI also links Dr. Mutyala to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mutyala practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Mutyala's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Mutyala is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Mutyala's licenses on file in 5 states: Arizona, Texas, New York, Massachusetts and Florida.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, cancer radiation-upper GI, cervical cancer radiation, colorectal cancer radiation and lung cancer radiation among the conditions Dr. Mutyala treats.

CMS data shows 7,330 Medicare services from Dr. Mutyala across 34 procedure codes in 2024, for 583 Medicare patients. Medicare paid $1,045,749 for them. Every service was in an office.

CMS counts 583 Medicare patients who saw Dr. Mutyala in 2024. The largest group is 65 to 74, with 272 patients. 75% of them have high cholesterol, and 72% have cancer. 5% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mutyala's median patient age at 73, with 51% women.

In 2024, Dr. Mutyala wrote 230 Medicare Part D claims for 88 patients. 90% of them were for generic drugs. CMS names the drug for 186 of them, across 6 drugs with 11 or more claims each, at $1,185 in total drug cost. In 2023, CMS named 157 claims across 5 drugs.

Dr. Mutyala accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Mutyala, published from 2011 to 2023. 2011 was the busiest year, with 2. The most frequent topics are Brachytherapy, Dose Fractionation, Radiation and Radiotherapy, Adjuvant. Dr. Mutyala has published most often in Brachytherapy. Dr. Mutyala's most frequent co-authors are Nitika Thawani, MD, Keyur J. Mehta, MD and Phillip Martin Devlin, MD.

Dmand AI links Dr. Mutyala to 1 clinical trial.

CMS Open Payments shows 162 general payments to Dr. Mutyala from 50 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. AstraZeneca Pharmaceuticals LP paid the most, $7,360.

Dmand AI lists 1 award for Dr. Mutyala, most recently Regional Top Doctor in 2014.

Dr. Mutyala graduated from Texas A&M College of Medicine - Bryan in 1999.

Dr. Mutyala is in network with 15 carriers, including United Healthcare, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.